Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report

doi:10.12998/wjcc.v9.i5.1175

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5414)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

338

WORD

175

HTML

2762

Figures (1-4)

496

Tables (1-1)

364

Sum=4135

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

445

Download

834

Sum=1279

Feb 16, 2021 (publication date) through Dec 31, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 16, 2021; 9(5): 1175-1183
Published online Feb 16, 2021. doi: 10.12998/wjcc.v9.i5.1175

Table 1 Evolution of therapy in our patient

Regimen	Duration of therapy (mo range)	Best response	Reason for stopping
Bortezomib/thalidomide/cyclophosphamide/dexamethasone (VTCD)	2 (Jun-Aug 2015)	PR	PR
Bortezomib/lenalidomide/cyclophosphamide/dexamethasone (VRCD)	9 (Aug 2015-May 2016)	CR	Started maintenance
Lenalidomide/dexamethasone (RD) Bortezomib/lenalidomide/dexamethasone (VRD) alternate maintenance	10 (May 2016-Mar 2017)	CR	PD
Bortezomib/lenalidomide/cyclophosphamide/dexamethasone (VRCD)	4 (Mar 2017-Jul 2017)	SD	SD
Isazomib/lenalidomide/cyclophosphamide/dexamethasone (IRCD)	11 (Jul 2017-Jun 2018)	CR	PD
BCMA CAR-T	15 (Jul 2018-Oct 2019)	CR	PD
Daratumumab/lenalidomide/dexamethasone (DRD)	2 (Oct 2019-Jan 2020)	PD	PD
Selinexor/dexamethasone	2 (Jan 2020-Mar 2020)	SD	SD
Chidaniline/venetoclax/dexamethasone	7 (Mar 2020-present)	VGPR	VGPR

BCMA: B cell maturation antigen; CAR-T: Chimeric antigen receptor T-cell immunotherapy; CR: Complete response; SD: Stable disease; PD: Progressive disease; PR: Partial response; VGPR: Very good partial response.

Citation: Yang Y, Fu LJ, Chen CM, Hu MW. Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report. World J Clin Cases 2021; 9(5): 1175-1183
URL: https://www.wjgnet.com/2307-8960/full/v9/i5/1175.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i5.1175